ALK raises financial expectations one week before Q2 report drops
The allergy firm says the upgrade is due to a strong sales momentum.
by mikkel holmgaard winding, translated by daniel pedersen
During the first half of 2022, allergy firm ALK has beat its own financial targets after ”a strong sales momentum,” which has now resulted in a guidance upgrade, according to a Thursday press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
ALK expects to have approved peanut allergy vaccine in 2030
For subscribers
ALK to start phase I trial of peanut allergy tablet vaccine
For subscribers
